Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
CHOLESTEROL COUNT: Three studies of the cholesterol-lowering drug Vytorin, funded by its makers, can't prove or rule out a possible link to a higher risk of cancer that emerged this summer.
EXPERT OPINION: Top editors of the New England Journal of Medicine are urging doctors and patients to use caution and stick with statins if they work well enough. Vytorin contains a now-generic statin, Zocor, and a cholesterol drug that works differently, Zetia.
PHARMACEUTICAL FALLOUT: The findings could hurt sales of pricey Vytorin, plus share of makers Merck & Co. and Schering-Plough Corp.
Next weeks G8 may shine the spotlight on the USD as the global standard
The U.S. economy likely shed a further 355,000 jobs in June and the unemployment...
Cisco live 2009 website is down and nobody can access the site for the latest in...
|
Effective and Affordable Press Release Distribution Service
Take profit from the markets roller coaster. No downloads, no commissions, no spreads.
Can predict currency pairs movements? Binary option trading is what you need. Click here.
Partners  
|
© 2009 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
-1.77
0.46
